Cancer reports最新文献

{"title":"Potential of Serum ApoC1 as a Noninvasive Biomarker for Breast Cancer Detection and Prognosis: A Prospective Case–Control Study","authors":"Abolfazl Khalafi-Nezhad,&nbsp;Mahdi Barazesh,&nbsp;Ahmad Abdollahi,&nbsp;Negin Kheiri,&nbsp;Marzieh Amani","doi":"10.1002/cnr2.70359","DOIUrl":"https://doi.org/10.1002/cnr2.70359","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Breast cancer (BC) is one of the most frequent malignancies. Apolipoprotein C1 (ApoC1) has been known as a promising therapeutic target and valuable prognostic and diagnostic biomarker in cancers. The aim of this study was to explore the diagnostic implication of serum ApoC1 concentration in new cases of BC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective case–control study was conducted on 76 new cases of BC patients referred to Amir-al-Momenin Gerash hospital. Subjects in the control group were 15 healthy individuals. The serum concentrations of ApoC1 of the control group and the BC patients were measured by ELISA assay. Data analysis was performed using Student's <i>t</i>-test and one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean age of the BC patients was 49.21 ± 10.42 years. In terms of diagnostic performance, ApoC1 concentration showed a significant down-regulation in female BC patients compared to healthy controls. The receiver operating characteristic (ROC) curve analysis indicated an area under the curve (AUC) of 1.00, demonstrating the excellent diagnostic value of ApoC1 in distinguishing BC patients from healthy individuals. The optimal cutoff value for ApoC1 concentration was determined to be 15.4 mg/dL, with 100% sensitivity, 100% specificity, and 100% accuracy. Furthermore, the prognostic analysis focused on HER2 over-expression patients demonstrated a statistically significant difference in ApoC1 concentration compared to other types of BC. The ROC curve analysis revealed the prognostic performance of ApoC1, with an optimal cutoff value of 5.6 mg/dL, 100% positive predictive value (PPV), and 100% negative predictive value (NPV).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>According to the findings of the current study, ApoC1 may be a potential serum biomarker for the diagnosis of BC. Moreover, ApoC1 can be considered a highly accurate prognostic biomarker for BC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Surgical Outcome After Oncovascular Surgery of Soft Tissue and Osteogenic Sarcomas of the Limbs","authors":"Sebastian Kapahnke,&nbsp;Matthias Bürger,&nbsp;Melanie Rusch,&nbsp;Grischa Hoffmann,&nbsp;Philipp Johannes Pauli,&nbsp;Lars Hummitzsch,&nbsp;Martin Albrecht,&nbsp;Roland Bertolini,&nbsp;Julia Bertolini,&nbsp;Rene Rusch,&nbsp;Rouven Berndt,&nbsp;Christoph Röcken,&nbsp;Daniel Drücke,&nbsp;Katharina Hess","doi":"10.1002/cnr2.70353","DOIUrl":"10.1002/cnr2.70353","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Soft tissue sarcomas (STS) and osteogenic sarcomas (OGS) of the limbs are rare diseases. Nowadays, most patients with STS or OGS undergo tumor resection and subsequent vascular reconstruction for potential limb preservation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Due to very limited data on these complex surgical procedures, the aim of this single-center, retrospective study was to evaluate the surgical and oncological outcomes of these patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From 2013 to 2023, demographic, clinical, surgical, and pathological data regarding tumor disease, surgical treatment, and postoperative care of a total of 10 patients with STS and OGS were identified and analyzed. Furthermore, overall survival (OS) and freedom from tumor recurrence (FFT) were retrospectively investigated among all patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean age of the patients was 64.4 ± 22.24 years, and six women (60%) and four men (40%) were treated. Overall, 16 major arterial and venous vessels were resected and reconstructed: the lower extremity was affected in nine patients (90%). Autologous veins (<i>n</i> = 12, 75%), polytetrafluoroethylene (PTFE; <i>n</i> = 2, 12.5%), or cryopreserved allografts (<i>n</i> = 2, 12.5%) were mainly used for vascular reconstruction. The follow-up ranged from 7 to 60 months, with a median OS of 48 months and a median FFT of 54 months. Overall, four patients (40%) developed local tumor recurrence at the primary surgical resection site or metastasis. The primary graft patency for all vascular reconstructions was 90% at the median follow-up of 24 months. All revascularized limbs among these patients could be salvaged during the follow-up period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Treatment of patients with STS or OGS of the limbs and subsequent vascular reconstruction can be performed safely and effectively. The outcomes described in this cohort suggest that an interdisciplinary team, including vascular surgeons and a carefully planned and rigorous clinical approach, might positively influence the postoperative and oncological outcome and limb salvage.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes and Toxicities in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immunotherapy Containing Regimens","authors":"Meghana Maddula,&nbsp;Lauren J. Brown,&nbsp;Venessa Chin,&nbsp;Bo Gao,&nbsp;Ines Pires Da Silva,&nbsp;Adnan Nagrial","doi":"10.1002/cnr2.70361","DOIUrl":"10.1002/cnr2.70361","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Immunotherapy is well-established in treating metastatic non-small cell lung cancer (mNSCLC); however, data regarding acquired resistance and long-term outcomes are limited. We examined long-term outcomes in mNSCLC patients with ongoing treatment response at 2 years (long-term responders) post-treatment commencement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multi-center retrospective study identified mNSCLC patients treated with first- or second-line immunotherapy±chemotherapy. Endpoints included progression-free survival (PFS) and overall survival (OS), stratified by PD-L1 tumor proportion score (TPS) (&lt; 50% vs. ≥ 50%), treatment duration, and treatment line.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 354 patients, 52 (15%) long-term responders were identified for analysis. Among them, median age was 68.5 years (28–87); the majority had an ECOG performance status ≤ 1 (81%), high-PD-L1 TPS (52%), and adenocarcinoma histopathology (83%). Most (73%) received immunotherapy first-line. Median treatment duration was 23.5 months (1–80), and 19% prematurely ceased treatment. With a median follow-up of 39 months from treatment commencement (95% CI 37–49), 15 (29%) patients had progressive disease, and 3-year PFS was 78%. Oligo-progression was common (87%), with lung/pleural disease (53%). Most received subsequent treatment (local therapy alone: 53%, systemic therapy alone: 20%, combined: 20%, supportive care: 7%) and achieved disease control (86%). Long-term toxicities occurred in 44% and were predominantly endocrinopathies (83%) requiring ongoing management. Three-year OS was 93%. Survival outcomes were unaffected by treatment duration, PD-L1 TPS, and treatment line.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Long-term responders showed favorable survival outcomes, with most maintaining disease control with local therapies even after progression. This held true regardless of treatment duration, PD-L1 TPS, or treatment line. Endocrinopathies were common long-term toxicities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70361","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatic Characterization of Genes That Are Correlated to the Progression of Breast Cancer to Breast Cancer Brain Metastasis","authors":"Mageshree Pillay,&nbsp;Oliver Tendayi Zishiri","doi":"10.1002/cnr2.70360","DOIUrl":"10.1002/cnr2.70360","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The incidence of breast cancer is escalating into millions of cases annually all over the world with hundreds of thousands of deaths recorded each year. It has been well established that breast cancer is caused by both genetic and non-genetic factors. However, there is a paucity of information on breast cancer that metastasizes to the brain. The molecular process of carcinogenesis in breast cancer brain metastasis (BCBM) is yet to be fully characterized.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>It is crucial to identify genes linked with breast cancer brain metastasis development and prognosis. This study sought out to decipher putative pathogenic and predictive genes in BCBM using bioinformatic analysis of public datasets.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The bioinformatic analysis utilized the GSE125989, GSE191230 and GSE52604 datasets. GEO2R was used for the identification of DEGs. Venn was employed to identify the common up-regulated and down-regulated genes. The STRING website was used to create the protein-protein interaction (PPI) network of the DEGs, which was then represented using Cytoscape. A Kaplan–Meier (KM) plotter was used to conduct the hub gene survival analysis. Validation of the hub genes was carried out using UALCAN. The heat map was then visualized using Fun Rich. The tumor infiltrating analysis was carried out using TIMER. Using DAVID, the GO and KEGG analyses were conducted. The structure of the hub genes was obtained from the human protein atlas. A total of 4 DEGs was identified. A PPI network was developed, one significant module was identified, and 3 clusters were selected. Ten hub genes were discovered using Cytoscape‘s MCC ranking technique. Ten hub genes (<i>IL6, INS, TNF, PPARG, PPARA, SLC2A4, PPARGC1A, IRS1, LEP</i> and <i>ADIPOQ</i>) were all associated with the progression of BCBM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study‘s findings revealed that the hub genes investigated could be possibly vital genes in determining the molecular mechanism of BCBM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12504803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145243936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Lung Cancer Metastasis Using Machine Learning Models Based on Clinical Laboratory Data","authors":"Chao Du,&nbsp;Qi Liu,&nbsp;Yuanyuan Guo,&nbsp;Jun Gong,&nbsp;Ling Yan,&nbsp;Zhijie Li,&nbsp;Changchun Niu","doi":"10.1002/cnr2.70350","DOIUrl":"10.1002/cnr2.70350","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lymph node (N) or/and distant metastasis in lung cancer indicates poorer prognosis. While laboratory tests and computed tomography (CT) scans reflect tumor growth and metabolic activity, they usually require combination with other diagnostic methods to effectively assess metastasis, resulting in limited clinical use of these results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Develop machine learning models using diverse clinical laboratory data to predict lymph node invasion and skip N metastasis in lung cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study performs regression analysis on lung cancer cases initially diagnosed by histopathology, categorized into N and M (skip N metastasis) groups by TNM stage. Laboratory and clinical test results were collected as characteristic parameters. Univariate analysis and lasso regression identified key predictors, and four machine learning algorithms developed the model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 1629 cases analyzed, 861 were assigned to the N group and 519 to the M group. Univariate analysis revealed significant differences in 40 parameters in Group N and 27 parameters in Group M (<i>p</i> &lt; 0.05). LASSO regression identified 13 characteristic factors for the N group and 12 for the M group. In the N group, the factors included tumor size, prothrombin time (PT), mean platelet volume, fibrinogen, platelet count, procalcitonin, carbohydrate antigen 15–3 (CA 15–3), carcinoembryonic antigen (CEA), adenosine deaminase, red blood cell distribution width, thrombin time, smoking history, and alcohol consumption history. In the M group, the factors included cytokeratin 19 fragment, tumor size, CEA, CA 15–3, squamous cell carcinoma antigen (SCCA), alkaline phosphatase, fibrinogen, hemoglobin, calcium, albumin, PT, and absolute monocyte count. The test cohort results indicated that the logistic regression model was optimal for both groups, achieving AUC values of 0.888 and 0.875, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study demonstrated the potential of using ML algorithms, laboratory data, and clinical features to predict N involvement and skip N metastasis in lung cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acinic Cell Carcinoma of the Breast: A Population-Based Clinicopathologic Study","authors":"Faruk Skenderi,&nbsp;Giridhara Rathnaiah Babu,&nbsp;Una Glamoclija,&nbsp;Emir Veledar,&nbsp;Zoran Gatalica,&nbsp;Janez Lamovec,&nbsp;Semir Vranic","doi":"10.1002/cnr2.70357","DOIUrl":"10.1002/cnr2.70357","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Acinic cell carcinoma (ACC) of the breast is a very rare, primary salivary gland-type breast malignancy, with ~100 reported cases in the literature. Limited information about the clinical features and outcomes of patients with ACC is available.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify ACC patients. For comparison, we also examined a cohort of invasive breast carcinomas of no special type (NST).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty ACC patients were identified among the more than 248 000 invasive breast carcinoma NST patients. ACCs were predominantly grade 3 carcinomas (44%) and were diagnosed at an earlier stage (67%). Hormone receptor (HR) and HER2 status data were available for only 13 patients, revealing molecular heterogeneity: HR−/HER2− (four patients), HR−/HER2+ (two patients), HR+/HER2− (four patients), and HR+/HER2+ (three patients). The median survival time for ACC patients was 19 months vs. 48 months for NST patients (<i>p</i> &lt; 0.001). A complete-case approach was utilized for the adjusted analyses, restricting the sample to 46 257 patients without missing data on all relevant covariates. The adjusted Kaplan–Meier analysis indicated a more pronounced decline in survival probabilities among patients with ACC compared to those with NST, with the number at risk in the ACC group diminishing to four patients by the 30-month mark. In contrast, NST patients exhibited a more gradual decrease. In the multivariable Cox regression, which adjusted for age, TNM stage, HR/HER2, and chemotherapy, ACC histology was correlated with a 1.69-fold increase in the hazard of death (HR: 1.69; 95% CI: 0.63–4.56), although this result was not statistically significant. Age and advanced stage continued to be strong predictors of poor survival, and the inclusion of an age–time interaction enhanced the model fit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Acinic cell carcinoma of the breast is a very rare primary breast malignancy. Our study indicates potentially aggressive clinical behavior in mammary ACC; however, findings must be interpreted cautiously given inherent SEER limitations, especially regarding histologic and molecular subtyping accuracy. Further centralized studies are urgently needed for the accurate characterization of this rare entity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modification of Pathological Nodal Classification for pT1b Esophageal Squamous Cell Carcinoma With Lymphovascular Invasion: Over 10-Year Experience","authors":"Jin-bo Li,&nbsp;Li-Hong Zhang,&nbsp;Chang-Sen Leng,&nbsp;Jun-Ying Chen,&nbsp;Jian-Hua Fu","doi":"10.1002/cnr2.70342","DOIUrl":"https://doi.org/10.1002/cnr2.70342","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lymphovascular invasion (LVI) adversely affects the survival of pT1b esophageal squamous cell carcinoma (ESCC). It is hypothesized that a modified stage classification of pT1b ESCC based on LVI may facilitate multidisciplinary therapy in LVI-positive patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The study aims to investigate the impact of LVI on pathological nodal classification for pT1b ESCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Surgically resected pT1b ESCC patients in Sun Yat-sen University Cancer Center between 2008 and 2018 were retrospectively reviewed. Tumor sections were re-assessed for LVI by gastrointestinal pathologists. The associations between patient survival and LVI were evaluated by the Log-rank method. A multivariate Cox regression model was applied to identify the impact of LVI on survival. Prognostic performance was assessed by Harrell's <i>C</i>-index. A total of 424 cases with the pT1b stage were included. The risk of LVI was significantly higher in patients with nodal positive status (<i>p</i> &lt; 0.001) and larger tumor size (<i>p</i> = 0.033). The 5-year OS for LVI+ patients were 50.3% versus 78.0% for LVI− (<i>p</i> &lt; 0.001). Multivariable analyses suggested that LVI (<i>p</i> = 0.021) and pN (<i>p</i> = 0.016) stages were two independent adverse prognostic factors in pT1b patients. When classifying LVI+ as an independent subgroup into the pN category, the modified pN staging system demonstrated a superior prognostic performance (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Tumors with LVI should be defined as a separate subclassification to accurately classify the prognostic category in pT1b patients. Further studies are required to investigate multidisciplinary therapies for LVI+ pT1b patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70342","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between the Volume Transfer Constant (Ktrans) From Dynamic Contrast-Enhanced Perfusion MR and HER2 Status in Breast Cancer Brain Metastases","authors":"Jonathan R. Young,&nbsp;Luke N. Ledbetter,&nbsp;Julie A. Ressler,&nbsp;Mark S. Shiroishi,&nbsp;Joanne E. Mortimer,&nbsp;Daniel Schmolze,&nbsp;Mariko Fitzgibbons,&nbsp;Bihong T. Chen","doi":"10.1002/cnr2.70354","DOIUrl":"https://doi.org/10.1002/cnr2.70354","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>With the development of new human epidermal growth factor 2 (HER2)-targeting therapies, a non-invasive method of determining the HER2 status of breast cancer brain metastases can be of great clinical value, particularly given the risks of brain biopsy and the possibility of discordance between HER2 status of the primary breast cancer and the brain metastasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The purpose of this study was to assess whether the volume transfer constant (Ktrans) from dynamic contrast-enhanced (DCE) perfusion brain MR could assist in identifying the HER2 status of breast cancer brain metastases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>With IRB approval for this retrospective study, we searched the electronic medical record at the City of Hope Comprehensive Cancer Center to identify all histopathologically proven breast cancer brain metastases with both preoperative DCE perfusion brain MR and HER2 assessment of the resected/biopsied brain specimens at the City of Hope Comprehensive Cancer Center from 2011-2022. Mann-Whitney tests were used to compare the Ktrans of the breast cancer brain metastases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 9 women in our study cohort with a mean age of 55 years. Our cohort was comprised of a total of 9 breast cancer brain metastases, 3 of which were HER2-positive, 6 of which were HER2-negative. The Ktrans of HER2-positive breast cancer brain metastases was significantly greater than the Ktrans of HER2-negative breast cancer brain metastases (0.09 min⁻¹ vs 0.02 min⁻¹, U = 18.00, <i>p</i> = 0.024).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Ktrans may help to differentiate HER2-positive from HER2-negative breast cancer brain metastases, if validated in a large prospective, multi-center trial.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70354","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Combination Androgen-Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly-Metastatic Prostate Cancer","authors":"Makoto Kawase,&nbsp;Kota Kawase,&nbsp;Yuki Tobisawa,&nbsp;Koji Iinuma,&nbsp;Keita Nakane,&nbsp;Takuya Koie","doi":"10.1002/cnr2.70355","DOIUrl":"https://doi.org/10.1002/cnr2.70355","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) has dramatically changed over the past decade. To improve oncological outcomes, pharmacological treatments have evolved to include two-or three-drug combinations, and the efficacy of local radiation therapy (LRT) at the prostate combined with denosumab chemotherapy has been discussed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to provide an interim evaluation of the combination of androgen receptor signaling inhibitors denosumab, LRT, and metastasis-directed therapy (MDT) for prostate cancer with multiple bone metastases (poly-PCa).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We are currently conducting a single-arm prospective study to evaluate the combination of enzalutamide, LRT, denosumab, and MDT in terms of improving oncological outcomes in patients with poly-PCa. The primary endpoints were prostate-specific antigen (PSA)-based progression-free survival (PFS) and radiographic PFS (rPFS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty patients have been enrolled in the study to date. The median follow-up period thus far is 18.0 months (interquartile range, 14.0–25.8 months). The 1-year PFS rate is 84.4% at present, and the rPFS rate is 100%. Seventeen patients (85.0%) achieved a PSA reduction of ≥ 90% versus their baseline values at enrollment, and 10 (50.0%) maintained PSA levels of &lt; 0.2 ng/mL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This treatment strategy is expected to improve the oncological outcomes of patients with poly-PCa. A more comprehensive report of this study with more patients and a longer observation period is forthcoming.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70355","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous Melanoma and Follicular Lymphoma in the Same Nodal Basin: A Diagnostic and Therapeutic Challenge.","authors":"Silvia Borriello, Umberto Santaniello, Matteo G Brizio, Paolo Fava, Giovanni Cavaliere, Giulia Carpentieri, Rebecca Senetta, Adriana Lesca, Simone Ribero, Pietro Quaglino, Franco Picciotto","doi":"10.1002/cnr2.70363","DOIUrl":"https://doi.org/10.1002/cnr2.70363","url":null,"abstract":"<p><strong>Background: </strong>The incidence of both malignant melanoma (MM) and non-Hodgkin lymphoma (NHL) has risen in recent decades, with studies suggesting a potential bidirectional association. Nonetheless, synchronous presentation of active disease in both entities remains rare.</p><p><strong>Case: </strong>We report the case of a 62-year-old man with a history of indolent B-cell lymphoma, exhibiting features between marginal zone and follicular subtype, previously treated with R-CHOP, radiotherapy, and Rituximab maintenance, achieving complete remission. Ten years later, he developed an ulcerated superficial spreading melanoma (Breslow thickness 4.5 mm, pT4b), with staging CT revealing right axillary lymphadenopathy. Biopsy confirmed relapsed follicular lymphoma. Surgical management included wide excision and sentinel lymph node biopsy, which identified melanoma metastasis in one sentinel node and confirmed FL in the non-sentinel node. Molecular testing showed a BRAFV600E mutation. The patient received axillary radiotherapy followed by adjuvant BRAF/MEK inhibitor therapy.</p><p><strong>Conclusion: </strong>At 6-month follow-up, imaging showed no evidence of relapse. This represents the first documented case of synchronous stage III BRAF-mutated MM and FL managed with targeted BRAF/MEK inhibitors combined with localized radiotherapy. The successful outcome validates this sequential multidisciplinary approach and underscores the importance of dermatologic surveillance in NHL survivors.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":"e70363"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}